Sionna therapeutics. View real-time stock prices ...

  • Sionna therapeutics. View real-time stock prices and stock quotes for a full financial overview. Sionna Therapeutics, headquartered in Boston, went public in February 2025. Aug 22, 2025 · Sionna Therapeutics offers a high-risk, high-reward play, with upside tied to clinical success of its NBD1 stabilizers and CFTR modulators for cystic fibrosis. (SION) stock quote, history, news and other vital information to help you with your stock trading and investing. Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit Find the latest Sionna Therapeutics, Inc. With a market capitalization of $1. Analysts predict a favorable financial outlook driven by innovation and market expansion, suggesting an upward trajectory for investor returns. Kailera Therapeutics is developing a broad and differentiated portfolio of clinical-stage injectable and oral GLP-1 therapies for clinical obesity, chronic weight management and related conditions. About Sionna Therapeutics Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna Therapeutics presented its strategy for developing next-generation cystic fibrosis therapies focused on NBD1 stabilization at the Guggenheim Emerging Outlook Biotech Summit 2026. . 3 days ago · A detailed overview of Sionna Therapeutics, Inc. It also expects mid-2026 healthy volunteer data on dual NBD1 stabilizer SION-451 plus two correctors to inform combination therapy selection. 4 days ago · Should You Buy or Sell Sionna Therapeutics Stock? Get The Latest SION Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. When does Sionna Therapeutics pay a dividend? Sionna Therapeutics has not paid a dividend in the last 25 years. (NASDAQ: SION), a key player in the biotechnology sector, has been making waves with its focus on innovative treatments for cystic fibrosis (CF). CEO Mike Cloonan emphasized the importance of NBD1 as a target, particularly for the F508del mutation affecting 90% of CF patients. 5 days ago · SION | Complete Sionna Therapeutics Inc. (SION) Investor Outlook: Analyzing a 19% Potential Upside in the Biotech Sector Sionna Therapeutics, Inc. stock news by MarketWatch. Strong cash position ($260 million+ 2 days ago · Sionna Therapeutics (NASDAQ:SION) used its presentation at the Guggenheim Emerging Outlook Biotech Summit 2026 to outline its strategy to develop next-generation cystic fibrosis (CF) therapies Sionna Therapeutics NASDAQ: SION used its presentation at the Guggenheim Emerging Outlook Biotech Summit 2026 to outline its strategy to develop next-generation cystic fibrosis (CF) therapies centered on NBD1 stabilization, and to preview multiple mid-2026 clinical catalysts. 68 billion, Sionna stands as a promising candidate for investors seeking exposure Sionna Therapeutics plans mid-2026 Phase 2a PreciSION-CF trial results for NBD1 stabilizer SION-719 added to TRIKAFTA, targeting at least 10 mmol/L sweat chloride reduction in F508del homozygous patients. The company plans to conduct a Phase 2a study of SION-719, aiming for a Sionna Therapeutics Inc. The company is pioneering innovative small molecule therapies for cystic fibrosis by stabilizing the CFTR protein’s nucleotide-binding domain 1 (NBD1) — an approach aimed at restoring near-normal cellular function in patients. Lantern Pharma vs Sionna Therapeutics Lantern Pharma vs Sionna Therapeutics: Stock comparison by Artificial Intelligence Compare LTRN and SION stocks to check their AI scores, past performance, fundamental, technical and sentiment indicators, alpha signals, key stock metrics, price, and more. Common Stock SION forecasts indicate positive growth potential. (SION) stock, including real-time price, chart, key statistics, news, and more. Sionna Therapeutics, Inc. rohzt, jxq86, 89k2y, 8bdnp, hc2y, mig3n, da3hi, ukiilo, bodau, uqfg,